0:35:34 · Salveen Richter, Goldman Sachs · RCC confidence
How confident is Moderna in the interim renal cell carcinoma readout, and what is its view on the LNP's contribution to immunogenicity in melanoma?
Management cited T-cell sensitivity of RCC and Phase 2 consistency for confidence, and said evidence that the LNP drives the effect is unclear and unlikely to explain such a strong hazard ratio. — Moderna management
0:38:18 · Terrence Flynn, Morgan Stanley · Pricing, RCC
What inputs go into pricing intismeran, and could a positive Phase 2 RCC study support registration?
Pricing is premature, while a positive RCC study would at minimum be practice-informing and could be taken to the FDA if results are very strong. — Stephen Hoge, David Berman
0:40:27 · Ellie Merle, Barclays · Pancreatic cancer
What are the next development steps for pancreatic cancer, and would an unsuccessful RCC interim be disclosed?
Next steps are being discussed with Merck, possibly the same chemotherapy regimen or a RAS inhibitor combination, and the disclosure approach has not been decided. — David Berman
0:42:13 · Edward Tendorf, Piper Sandler · BLA, lung cancer
What remains for the intismeran BLA, and when could lung cancer studies read out?
Moderna and Merck are working to submit this year and hope for approval next year, while lung readout timing is too early to predict. — Stephen Hoge, David Berman
0:44:36 · Alex Tranihan, Bank of America · mRNA-2808, guidance
What will the mRNA-2808 ASH update add, and how much of the revenue guidance raise is timing or pulled from 2027?
The ASH data will have more patients and longer follow-up, and management described the 2026 growth as broad-based across the U.S. and international markets rather than addressing pull-forward directly. — David Berman, Jamey Mock
0:47:26 · Miles Minter, William Blair · Norovirus
Why is Moderna not enrolling another norovirus cohort and what does it want from regulators?
After reviewing the program, Moderna judged consulting regulators the better next step and will update once those discussions occur. — Stephen Hoge
0:48:35 · Tyler Van Vuren, TD Cowen · RCC antigens
Can intismeran antigen selection capture endogenous retroviral elements that may drive RCC immunogenicity?
The algorithm includes indels and single-point neoantigens, and the retroviral hypothesis is speculative and needs more research. — David Berman
0:50:27 · Andrew Sy, Jefferies · Algorithm moat
Does the BLA need separate FDA approval of the algorithm, and why can't AI-enabled competitors catch up?
The selection algorithm is part of the drug, and Moderna says its growing proprietary trial data on neoantigens and T cell responses is a differentiator. — Stephen Hoge
0:53:28 · Michael Yee, UBS · Trial design, BLA
Does Moderna stand by the assumptions in the RCC and bladder trial protocols, and what is the melanoma filing timing?
Moderna was not aware of the protocols cited and gave no further timing beyond working closely with Merck on the BLA. — Stephen Hoge
0:54:46 · Courtney Breeden-Bernstein, Bernstein · Pancreatic, international
What does the pancreatic efficacy data show, and how much international revenue is committed versus demand-driven?
Efficacy signals are too early to interpret, and a significant, durable portion of international revenue comes from strategic partnerships alongside share gains and improving vaccination rates. — David Berman, Jamey Mock
0:57:45 · Alexandra Hammond, Wolfe Research · Neoantigen count
What has Moderna learned about the optimal number of neoantigens in intismeran?
34 neoantigens is enough in melanoma and it is unclear that more would help, with Phase 3 data to be used to decode this. — David Berman
0:59:24 · Jess Fai, JPMorgan · Translational data
Does Moderna have enough samples from Phase 3 to analyze the optimal number of neoantigens?
More patients are available than the seven in Phase 2, and new methods to infer neoantigen specificity from blood expression data may yield insights. — David Berman
1:01:09 · Lucas, RBC · RCC, combination vaccine
How is the RCC trial stratified, and what is the status of FDA talks on the U.S. flu/COVID combination?
Moderna believes intismeran can work across RCC subpopulations, and the U.S. combination path awaits FDA discussions over the coming months. — David Berman, Stephen Hoge